160 related articles for article (PubMed ID: 36374556)
21. Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo.
Yue P; Zhu Y; Brotherton-Pleiss C; Fu W; Verma N; Chen J; Nakamura K; Chen W; Chen Y; Alonso-Valenteen F; Mikhael S; Medina-Kauwe L; Kershaw KM; Celeridad M; Pan S; Limpert AS; Sheffler DJ; Cosford NDP; Shiao SL; Tius MA; Lopez-Tapia F; Turkson J
Cancer Lett; 2022 May; 534():215613. PubMed ID: 35276290
[TBL] [Abstract][Full Text] [Related]
22. Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3).
Huang Q; Zhong Y; Li B; Ouyang S; Deng L; Mo J; Shi S; Lv N; Wu R; Liu P; Hu W; Zhang X; Wang Y
Eur J Med Chem; 2021 Oct; 221():113525. PubMed ID: 34000483
[TBL] [Abstract][Full Text] [Related]
23. Valtrate as a novel therapeutic agent exhibits potent anti-pancreatic cancer activity by inhibiting Stat3 signaling.
Chen L; Feng D; Qian Y; Cheng X; Song H; Qian Y; Zhang X; Wu Y; Lv H; Liu Q; Cheng G; Yang B; Gu M
Phytomedicine; 2021 May; 85():153537. PubMed ID: 33744595
[TBL] [Abstract][Full Text] [Related]
24. A small molecule compound targeting STAT3 DNA-binding domain inhibits cancer cell proliferation, migration, and invasion.
Huang W; Dong Z; Wang F; Peng H; Liu JY; Zhang JT
ACS Chem Biol; 2014 May; 9(5):1188-96. PubMed ID: 24661007
[TBL] [Abstract][Full Text] [Related]
25. Identification of novel STAT3 inhibitors bearing 2-acetyl-7-phenylamino benzofuran scaffold for antitumour study.
Wang F; Feng KR; Zhao JY; Zhang JW; Shi XW; Zhou J; Gao D; Lin GQ; Tian P
Bioorg Med Chem; 2020 Dec; 28(24):115822. PubMed ID: 33126089
[TBL] [Abstract][Full Text] [Related]
26. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
[TBL] [Abstract][Full Text] [Related]
27. Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway.
Yang L; Lin S; Kang Y; Xiang Y; Xu L; Li J; Dai X; Liang G; Huang X; Zhao C
J Exp Clin Cancer Res; 2019 Jan; 38(1):31. PubMed ID: 30674340
[TBL] [Abstract][Full Text] [Related]
28. A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis.
Auzenne EJ; Klostergaard J; Mandal PK; Liao WS; Lu Z; Gao F; Bast RC; Robertson FM; McMurray JS
J Exp Ther Oncol; 2012; 10(2):155-62. PubMed ID: 23350355
[TBL] [Abstract][Full Text] [Related]
29. MLS-2384, a new 6-bromoindirubin derivative with dual JAK/Src kinase inhibitory activity, suppresses growth of diverse cancer cells.
Liu L; Gaboriaud N; Vougogianopoulou K; Tian Y; Wu J; Wen W; Skaltsounis L; Jove R
Cancer Biol Ther; 2014 Feb; 15(2):178-84. PubMed ID: 24100507
[TBL] [Abstract][Full Text] [Related]
30. SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation.
Duan Z; Bradner JE; Greenberg E; Levine R; Foster R; Mahoney J; Seiden MV
Clin Cancer Res; 2006 Nov; 12(22):6844-52. PubMed ID: 17121906
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of a novel oral signal transducer and activator of transcription 3 inhibitor YHO-1701.
Nishisaka F; Taniguchi K; Tsugane M; Hirata G; Takagi A; Asakawa N; Kurita A; Takahashi H; Ogo N; Shishido Y; Asai A
Cancer Sci; 2020 May; 111(5):1774-1784. PubMed ID: 32112605
[TBL] [Abstract][Full Text] [Related]
32. XZH-5 inhibits STAT3 phosphorylation and enhances the cytotoxicity of chemotherapeutic drugs in human breast and pancreatic cancer cells.
Liu A; Liu Y; Jin Z; Hu Q; Lin L; Jou D; Yang J; Xu Z; Wang H; Li C; Lin J
PLoS One; 2012; 7(10):e46624. PubMed ID: 23056374
[TBL] [Abstract][Full Text] [Related]
33. Cryptotanshinone suppresses the proliferation and induces the apoptosis of pancreatic cancer cells via the STAT3 signaling pathway.
Ge Y; Yang B; Chen Z; Cheng R
Mol Med Rep; 2015 Nov; 12(5):7782-8. PubMed ID: 26459366
[TBL] [Abstract][Full Text] [Related]
34. Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3).
Brambilla L; Genini D; Laurini E; Merulla J; Perez L; Fermeglia M; Carbone GM; Pricl S; Catapano CV
Mol Oncol; 2015 Jun; 9(6):1194-206. PubMed ID: 25777967
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of β-catenin signaling suppresses pancreatic tumor growth by disrupting nuclear β-catenin/TCF-1 complex: critical role of STAT-3.
Pramanik KC; Fofaria NM; Gupta P; Ranjan A; Kim SH; Srivastava SK
Oncotarget; 2015 May; 6(13):11561-74. PubMed ID: 25869100
[TBL] [Abstract][Full Text] [Related]
36. HAb18G/CD147 promotes pSTAT3-mediated pancreatic cancer development via CD44s.
Li L; Tang W; Wu X; Karnak D; Meng X; Thompson R; Hao X; Li Y; Qiao XT; Lin J; Fuchs J; Simeone DM; Chen ZN; Lawrence TS; Xu L
Clin Cancer Res; 2013 Dec; 19(24):6703-15. PubMed ID: 24132924
[TBL] [Abstract][Full Text] [Related]
37. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.
Nagaraj NS; Washington MK; Merchant NB
Clin Cancer Res; 2011 Feb; 17(3):483-93. PubMed ID: 21266529
[TBL] [Abstract][Full Text] [Related]
38. The anti-dysenteric drug fraxetin enhances anti-tumor efficacy of gemcitabine and suppresses pancreatic cancer development by antagonizing STAT3 activation.
Guo Y; Xiao Y; Guo H; Zhu H; Chen D; Wang J; Deng J; Lan J; Liu X; Zhang Q; Bai Y
Aging (Albany NY); 2021 Jul; 13(14):18545-18563. PubMed ID: 34320467
[TBL] [Abstract][Full Text] [Related]
39. Fraxetin Suppresses Proliferation of Non-Small-Cell Lung Cancer Cells via Preventing Activation of Signal Transducer and Activator of Transcription 3.
Zhang Y; Wang L; Deng Y; Zhao P; Deng W; Zhang J; Luo J; Li R
Tohoku J Exp Med; 2019 May; 248(1):3-12. PubMed ID: 31080186
[TBL] [Abstract][Full Text] [Related]
40. Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer.
Gong J; Xie J; Bedolla R; Rivas P; Chakravarthy D; Freeman JW; Reddick R; Kopetz S; Peterson A; Wang H; Fischer SM; Kumar AP
Clin Cancer Res; 2014 Mar; 20(5):1259-73. PubMed ID: 24520096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
